Toronto, Canada; Glil Yam, Israel – October 8, 2020 – IM Cannabis Corp. (the “Company” or “IMC”) (CSE:IMCC), a multi-country operator (“MCO”) in the medical cannabis sector with operations in Israel and across Europe, is pleased to announce that it has applied to list...
Shipments made to seven distribution partners in Germany German operations and growing sales by Focus Medical create inflection point to positive adjusted EBITDA profitability beginning in September 2020 IMC Netherlands has submitted its application to the Dutch...
Israeli Ministry of Health announced that it will begin accepting applications for a medical cannabis export Pilot Program IMC well positioned to leverage German EU-GMP certified subsidiary under the export Pilot Program to distribute IMC-branded medical cannabis...
IMC has now completed shipments of its branded flower products to four of the Company’s ten distribution partners, marking IMC’s official brand launch in Germany Three additional purchase commitments executed with German distributors IMC now has binding purchase...
First shipment received into Germany from EU-GMP supply partner, allowing the Company to begin fulfilling purchase commitments for IMC-branded products Adjupharm adds Cansativa, Ilios and Farmako to its distribution network, platform now includes ten distributors *...
Consolidated revenue increased to $3.8 million in Q2 2020, from $2.3 million in the prior year, a 62% increase, and a 180% increase over Q1 2020 Gross margin before fair value impacts was 54% in Q2 2020 Q2 2020 milestones include: Six pharmacy sales agreements signed...
